North America AI In Drug Repurposing Market Size, Share & Industry Analysis Report By Component (Software & Platform, and Services), By Technology (Machine Learning/Deep Learning, Natural Language Processing (NLP), Knowledge Graphs & Network-Based AI, Gen

The North America AI In Drug Repurposing Market would witness market growth of 19.2% CAGR during the forecast period (2025-2032).

The US market dominated the North America AI In Drug Repurposing Market by Country in 2024, and would continue to be a dominant market till 2032; thereby, achieving a market value of $1,311.4 million by 2032. The Canada market is experiencing a CAGR of 21.8% during (2025 - 2032). Additionally, The Mexico market would exhibit a CAGR of 21.8% during (2025 - 2032). The US and Canada led the North America AI In Drug Repurposing Market by Country with a market share of 81.9% and 11% in 2024.

North America has become a global center for using artificial intelligence in drug discovery and repurposing. This is thanks to its strong research and development infrastructure, large biomedical datasets, and strong regulatory bodies. Digital health records and genomics databases sped up the shift from manually repurposing drugs to AI-driven modeling. This helped researchers and startups find new drug-disease connections. Collaborations between AI companies and big drug companies in innovation hubs like Boston and Silicon Valley have turned AI repurposing from an academic field into a commercialized, clinical-stage field. This is because of access to proprietary data, computational power, and knowledge of regulations.

Some of the most important trends in this ecosystem are the use of real-world evidence to improve predictive validation, the rise of explainable AI to meet regulatory and scientific standards for openness, and the growing focus on rare diseases, which is supported by North American orphan drug policies. Competitive strategies focus on forming deep co-development partnerships with pharmaceutical research and development, creating unique data assets, and using hybrid business models that combine licensing with developing assets in-house. As competition heats up between AI-biotech companies, pharmaceutical divisions, and new tech companies, success depends more and more on combining biological insight, data exclusivity, model interpretability, and clinical validation to make sure that the results are useful and accepted by regulators.

Technology Outlook

Based on Technology, the market is segmented into Machine Learning/Deep Learning, Natural Language Processing (NLP), Knowledge Graphs & Network-Based AI, Generative AI & Large Language Models (LLMs), and Computer Vision. The Machine Learning/Deep Learning market segment dominated the US AI In Drug Repurposing Market by Technology is expected to grow at a CAGR of 17.2 % during the forecast period thereby continuing its dominance until 2032. Also, The Computer Vision market is anticipated to grow as a CAGR of 22.6 % during the forecast period during (2025 - 2032).

End Use Outlook

Based on End Use, the market is segmented into Pharmaceutical & BioTechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutes, and Other End Use. Among various Canada AI In Drug Repurposing Market by End Use; The Pharmaceutical & BioTechnology Companies market achieved a market size of USD $27.1 Million in 2024 and is expected to grow at a CAGR of 21.3 % during the forecast period. The Academic & Research Institutes market is predicted to experience a CAGR of 22.7% throughout the forecast period from (2025 - 2032).

Country Outlook

The US is the leader in the global AI drug repurposing market because of its advanced biotech ecosystem, strong pharmaceutical infrastructure, and culture of quick innovation. Strong partnerships between AI developers, pharmaceutical companies, and research institutions, backed by large biomedical data and government programs, have sped up the use of AI in drug discovery and repurposing. The market is moving toward platform-based models that use deep learning and network biology. There is also a growing focus on explainable AI and real-world evidence. Even though there are problems like data privacy and gaps in clinical validation, growth is still happening thanks to strategic partnerships and open regulations. So, the U.S. is the most important place for technological and scientific progress in AI-driven drug repurposing.

List of Key Companies Profiled

• Ginkgo Bioworks Holdings, Inc.
• IBM Corporation
• Atomwise, Inc.
• Cyclica, Inc.
• Genesis Healthcare Co.
• Verge, Inc.
• Novartis AG
• Schrödinger, Inc
• Recursion Pharmaceuticals, Inc.
• The Cradle Company

North America AI In Drug Repurposing Market Report Segmentation

By Component

• Software & Platform
• Services

By Technology

• Machine Learning/Deep Learning
• Natural Language Processing (NLP)
• Knowledge Graphs & Network-Based AI
• Generative AI & Large Language Models (LLMs)
• Computer Vision

By End Use

• Pharmaceutical & BioTechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Other End Use

By Application

• Oncology
• Neurology
• Infectious Diseases
• Rare & Orphan Diseases
• Cardiology
• Other Application

By Country

• US
• Canada
• Mexico
• Rest of North America

Show more